HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2004.065250v1 90/4/F301    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Patole, S Articles by Doherty, D Search for Related Content PubMed PubMed Citation Articles by Patole, S Articles by Doherty, D Topic Collections Relevant Article

Erythromycin as a prokinetic agent in preterm neonates: a systematic review

¹ Department of Neonatal Paediatrics, King Edward Memorial Hospital for Women, University of Western Australia, Perth, Western Australia
² Women and Infants Research Foundation at King Edward Memorial Hospital for Women and School of Women’s and Infant’s Health at University of Western Australia

Correspondence to:
Correspondence to:
Dr Patole
Department of Neonatal Paediatrics, KEM Hospital for Women, University of Western Australia, Perth, Western Australia 6008; skpatole{at}hotmail.com

Background: It often takes several days or even weeks to establish full enteral feeds (FEFs) in preterm, especially extremely low birthweight neonates because of feed intolerance related to gastrointestinal hypomotility. Clinical trials of erythromycin as a prokinetic agent in preterm neonates have reported conflicting results.

Aim: To systematically review the efficacy and safety of erythromycin as a prokinetic agent in preterm neonates.

Methods: Only randomised controlled trials in preterm neonates (gestation 37 weeks) were considered eligible for inclusion. The primary outcome was the time to reach FEFs of 150 ml/kg/day. The secondary outcomes included the incidence of erythromycin related adverse effects such as diarrhoea, cardiac arrhythmias, and hypertrophic pyloric stenosis. No restrictions were applied on the dose (low: 3–12 mg/kg/day; antimicrobial: 12 mg/kg/6–8 hours) and route (oral or intravenous) and mode (prophylactic or rescue) of administration. The standard methodology for systematic reviews was followed. A subgroup analysis was preplanned based on the dose and mode of drug administration.

Results: Seven trials (three prophylaxis, four rescue) with various doses, routes and modes of administration, and durations of erythromycin treatment and different results were found to be eligible for inclusion in the analysis. Meta-analysis could not be performed, as specific data were either inadequate or not available.

Conclusion: The conflicting trial results may be explained by differences in dose and route and mode of administration of erythromycin and in gastrointestinal motor responses in the presence of different feeding conditions—for example, fasting v fed state, intermittent v continuous feeds. Gestational and postnatal ages during erythromycin treatment are also important.

Abbreviations: FEF, full enteral feed; MMC, migrating motor complex

Keywords: enteral; erythromycin; feeding; preterm

Relevant Article

Fantoms

Martin Ward Platt
Arch. Dis. Child. Fetal Neonatal Ed. 2005 90: F283. [Extract] [Full Text] [PDF]